secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-04-15T23:59:59+00:00
Accession:  0001193125-26-155978
Event type: leadership
Sentiment:  positive
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics appoints Dr. Charles Q. Morris as Chief Medical Officer effective April 20, 2026
--------------------------------------------------------------------------------

- Dr. Morris, age 61, brings over 30 years of oncology drug development experience; most recently CMO at Lava Therapeutics.
- Annual base salary of $535,000, target bonus of 40% of base, and option for 450,000 PRLD shares vesting over 4 years.
- Severance provides 9 months salary/benefits (or 12 months plus full bonus and equity acceleration in change-of-control context).
- Company highlights his role will be critical as lead programs in MPN and ER+ breast cancer enter clinical development in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526155978/0001193125-26-155978-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526155978/prld-20260415.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-155978

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer